Home
Applications
Indications
Business
EpiSwitch™
Products
EpiSwitch™ Service
Investors
Investors Overview
Results and Presentations
Share Price Information
Regulatory News
Board & Governance
Key Corporate Documents
AIM Rule 26
Email Alerts
Investor Contacts
News
About Us
History
Board of Directors
Management Team
Scientific Advisory Panel
Values
Careers
Milestones
EpiSwitch™ used in diagnosis of canine lymphoma
Press Release
by Aroul Ramadass
Oxford Biodynamics Plc enters into master service agreement with world leading US pharmaceutical company to evaluate EpiSwitch™ biomarkers
Press Release
by oxfordbiodynamics
OBD joins ALS Biomarker study sponsored by Mitsubishi Tanabe Pharma America
Press Release
by oxfordbiodynamics
Oxford BioDynamics receives Queen's Award for Enterprise
Press Release
by oxfordbiodynamics
Oxford BioDynamics joins Imperial College London in a trial evaluating novel methods of screening for prostate cancer
Press Release
by oxfordbiodynamics
Collaboration agreement with Casa Sollievo della Sofferenza signed for the blood-based diagnosis of Autism Spectrum Disorder
Press Release
by Aroul Ramadass
Fifth collaboration agreement signed in immuno-oncology space
Press Release
by Aroul Ramadass
Consortium including Oxford BioDynamics receives €4 million Horizon 2020 award
Press Release
by Aroul Ramadass
Leading Chinese Healthcare Investment Group Takes Stake in Oxford Biodynamics Plc
Press Release
by oxfordbiodynamics
Canadian patent for EpiSwitch™ granted
Press Release
by Aroul Ramadass
1
2
3
…
13
Privacy Preference Center
Privacy Preferences
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with this.
Ok
Read more
